- Home
- FULC vs PROK Comparison
FULC vs PROK Comparison
Compare FULC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- PROK
- Stock Information
- Founded
- FULC 2015
- PROK 2015
- Country
- FULC United States
- PROK United States
- Employees
- FULC N/A
- PROK N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FULC Health Care
- PROK Health Care
- Exchange
- FULC Nasdaq
- PROK Nasdaq
- Market Cap
- FULC 469.0M
- PROK 417.1M
- IPO Year
- FULC 2019
- PROK N/A
- Fundamental
- Price
- FULC $7.87
- PROK $2.70
- Analyst Decision
- FULC Buy
- PROK Strong Buy
- Analyst Count
- FULC 7
- PROK 4
- Target Price
- FULC $10.43
- PROK $6.25
- AVG Volume (30 Days)
- FULC 618.0K
- PROK 1.8M
- Earning Date
- FULC 10-29-2025
- PROK 11-12-2025
- Dividend Yield
- FULC N/A
- PROK N/A
- EPS Growth
- FULC N/A
- PROK N/A
- EPS
- FULC N/A
- PROK N/A
- Revenue
- FULC N/A
- PROK $527,000.00
- Revenue This Year
- FULC N/A
- PROK $471.74
- Revenue Next Year
- FULC N/A
- PROK N/A
- P/E Ratio
- FULC N/A
- PROK N/A
- Revenue Growth
- FULC 2752.05
- PROK N/A
- 52 Week Low
- FULC $2.32
- PROK $0.46
- 52 Week High
- FULC $10.11
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- FULC 40.58
- PROK 40.65
- Support Level
- FULC $8.42
- PROK $2.90
- Resistance Level
- FULC $9.47
- PROK $3.27
- Average True Range (ATR)
- FULC 0.80
- PROK 0.22
- MACD
- FULC -0.21
- PROK -0.07
- Stochastic Oscillator
- FULC 7.11
- PROK 0.00
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.